- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 08:02 | Hemogenyx Pharmaceuticals PLC Announces Collaboration and Company Update | 123 | ACCESS Newswire | Collaboration with Vilnius University Hospital Santaros Klinikos on HG-CT-1 Clinical Application and Research LONDON, UK / ACCESS Newswire / July 29, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)... ► Artikel lesen | |
| 08:00 | Hemogenyx Pharma Plc - Collaboration and Company Update | 4 | RNS | ||
| 01.07. | Hemogenyx Pharma Plc - Result of AGM | - | RNS | ||
| 05.06. | Hemogenyx Pharmaceuticals PLC Announces Notice of AGM | 259 | ACCESS Newswire | Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Posting of Annual Report & Notice of Annual General Meeting LONDON, UK / ACCESS Newswire / June 5, 2026 / Hemogenyx Pharmaceuticals... ► Artikel lesen | |
| 05.06. | Hemogenyx Pharma Plc - Notice of AGM | - | RNS | ||
| 29.05. | Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant Term | 262 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 29.05. | Hemogenyx Pharmaceuticals gibt neue Aktienoptionen aus und verlängert Laufzeit von Optionsscheinen | 4 | Investing.com Deutsch | ||
| 29.05. | Hemogenyx Pharma Plc - Grant of Options and Extension of Warrant Term | 1 | RNS | ||
| 30.04. | Hemogenyx Pharmaceuticals PLC Announces Final Results | 251 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 30.04. | Hemogenyx Pharma Plc - Final Results | 3 | RNS | ||
| 28.04. | Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise | 235 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 28.04. | Hemogenyx Pharma Plc - Institutional Fundraise | 3 | RNS | ||
| 14.04. | Hemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDA | 339 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 14.04. | Hemogenyx Pharma Plc - Annual IND Report with FDA | 1 | RNS | ||
| 31.03. | Hemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial Update | 208 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 31.03. | Hemogenyx completes tech transfer for CAR-T therapy to CDMO | 4 | Investing.com | ||
| 31.03. | Hemogenyx: Technologietransfer für CAR-T-Therapie erfolgreich abgeschlossen | 2 | Investing.com Deutsch | ||
| 31.03. | Hemogenyx Pharma Plc - Tech Transfer Completion and Clinical Trial Update | 2 | RNS | ||
| 27.02. | Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights | 342 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / February 27, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the... ► Artikel lesen | |
| 27.02. | Hemogenyx Pharma Plc - Total Voting Rights | 3 | RNS |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,505 | -0,33 % | SCHOCKMELDUNG bei InnoCan Pharma: Das Warnsignal das die meisten Anleger jetzt übersehen - Das habe ich heute entschieden | ||
| NOVERIS HEALTH SCIENCES | 0,815 | +10,88 % | XFRA 0NF1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PEAKBIRCH COMMERCE | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.02.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 02.02.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.02.2026ISIN NameCA70470T2092 PEAKBIRCH... ► Artikel lesen | |
| BIOHAVEN | 13,760 | -0,04 % | Biohaven Aktie legt nach positivem Gerichtsurteil zu | ||
| BAYER | 46,820 | -0,45 % | Bayer-Aktie: DAX-Schlusslicht - heißer August voraus | Die Euphorie ist nach der positiven Entscheidung des Supreme Courts zugunsten des DAX-Konzerns in der Causa Glyphosat und positiven Analystenkommentaren verflogen. Zur Wochenmitte rangiert die Bayer-Aktie... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 46,640 | -0,04 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,120 | -0,15 % | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | ||
| AQUESTIVE THERAPEUTICS | 3,760 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 71,62 | -0,47 % | Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? | ||
| NOVO NORDISK | 44,885 | +0,53 % | Novo Nordisk, Eli Lilly und GSK investieren Milliarden - warum Biotech plötzlich wieder zum Übernahmekandidaten wird | ||
| MERCK KGAA | 144,10 | -0,10 % | DEUTSCHE BANK RESEARCH stuft MERCK KGAA auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Merck KGaA vor Quartalszahlen auf "Hold" mit einem Kursziel von 125 Euro belassen. Der Pharma- und Technologiekonzern dürfte... ► Artikel lesen | |
| LB PHARMACEUTICALS | 34,940 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia | NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,070 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update | CARDAMYST (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company... ► Artikel lesen | |
| TRISALUS LIFE SCIENCES | 4,330 | 0,00 % | Canaccord reiterates TriSalus stock Buy rating after KOL event | ||
| KARDIGAN | 20,980 | -0,05 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen |
HEMOGENYX PHARMACEUTICALS PLC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 7,900 Euro und damit -6,51 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOGENYX PHARMACEUTICALS PLC finden Sie auf Wallstreet Online.